REDWOOD CITY, Calif., Nov. 29, 2011 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from sixteen studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 6-10, 2011 at the Henry B. Gonzalez Convention Center. The SABCS press briefing on Wednesday, December 7 at 7:30 AM Central Time, will include the findings of the DCIS study.
Presentations include:
- Oral presentation of the complete results from a study of Oncotype DX® in patients with DCIS (ductal carcinoma in situ of the breast) conducted by the Eastern Cooperative Oncology Group (ECOG)
- The first clinical outcomes study for biomarker discovery using next generation sequencing (NGS) technology in fixed paraffin embedded tissue
- Multiple international studies on the impact of Oncotype DX on changing treatment decisions and/or the test’s cost effectiveness in the United Kingdom, Germany, France, Ireland, Israel, Canada, Hungary, Japan, Singapore, Australia, and Venezuela
